347186-70-3

Basic information

• Product Name: 3-Pyridine Acetic Acid-Alpha-Bromo Ethyl Ester
• Synonyms: 3-Pyridine Acetic Acid-Alpha-Bromo Ethyl Ester;ethyl 2-bromo-2-(pyridin-3-yl)acetate
• CAS NO: 347186-70-3
• Molecular Formula: C₉H₁₀BrNO₂
• Molecular Weight: 244.0852
• Mol File: 347186-70-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 300.2±27.0 °C(Predicted)
• Appearance: /
• Density: 1.471±0.06 g/cm3(Predicted)
• PKA: 3.32±0.11(Predicted)
• CAS DataBase Reference: 3-Pyridine Acetic Acid-Alpha-Bromo Ethyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridine Acetic Acid-Alpha-Bromo Ethyl Ester(347186-70-3)
• EPA Substance Registry System: 3-Pyridine Acetic Acid-Alpha-Bromo Ethyl Ester(347186-70-3)

Safety Data

• Hazardous Substances Data: 347186-70-3(Hazardous Substances Data)

Upstream product

• 39931-77-6 pyridin-3-yl-acetic acid ethyl ester 

Downstream Products

• 83871-61-8 DL-N-Phenyl-pyrid-3-yl-glycinethylester 
• 1218416-83-1 C₁₅H₁₅FN₂O₂ 
• 1338494-40-8 C₂₀H₂₃ClFN₃O₃ 
• 1338494-39-5 C₂₀H₂₁ClFN₃O₂ 
• 1338494-70-4 C₁₈H₂₂FN₃O₂ 
• 1338494-68-0 C₁₈H₂₀FN₃O 
• 1218317-64-6 C₁₃H₁₁FN₂O₂ 

Relevant articles and documents

Potent and selective inhibitors of glutathione S-transferase omega 1 that impair cancer drug resistance

Glutathione S-transferases (GSTs) are a superfamily of enzymes that conjugate glutathione to a wide variety of both exogenous and endogenous compounds for biotransformation and/or removal. Glutathione S-tranferase omega 1 (GSTO1) is highly expressed in human cancer cells, where it has been suggested to play a role in detoxification of chemotherapeutic agents. Selective inhibitors of GSTO1 are, however, required to test the role that this enzyme plays in cancer and other (patho)physiological processes. With this goal in mind, we performed a fluorescence polarization activity-based protein profiling (fluopol-ABPP) high-throughput screen (HTS) with GSTO1 and the Molecular Libraries Small Molecule Repository (MLSMR) 300K+ compound library. This screen identified a class of selective and irreversible α-chloroacetamide inhibitors of GSTO1, which were optimized to generate an agent KT53 that inactivates GSTO1 with excellent in vitro (IC50 = 21 nM) and in situ (IC50 = 35 nM) potency. Cancer cells treated with KT53 show heightened sensitivity to the cytotoxic effects of cisplatin, supporting a role for GSTO1 in chemotherapy resistance.

CATHEPSIN B INHIBITORS

Compounds of formula I, including individual diastereomers thereof and pharmaceutically acceptable salts and hydrates thereof, are selective inhibitors of cathepsin B, and are useful in treating pathological conditions that are treated by inhibiting cathepsin B.